`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`SAMSUNGBIOEPIS CO., LTD., CELLTRION INC,
`and BIOCON BIOLOGICSINC.
`Petitioners,
`
`Vv.
`
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner.
`
`Patent No. 11,253,572
`
`Inter Partes Review No. IPR2023-00884!
`
`
`
`PATENT OWNER’S UPDATED POWEROF ATTORNEY
`UNDER37C.F.R.§ 42.10(b)
`
`
`
`1 [PR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.
`
`
`
`IPR2023-00884
`
`Patent Owner, Regeneron Pharmaceuticals, Inc., hereby appoints the following
`
`practitioners as its attorneys to transact all business in the United States Patent and
`
`Trademark Office associated with the above-captioned inter partes review of U.S.
`
`Patent No. 11,253,572.
`
`Adam R.Brausa, Reg. No. 60,287
`
`Rebecca Weires, Reg. No. 77,895
`
`Daralyn J. Durie, (pro hac vice, granted)
`
`Kira A. Davis, (pro hac vice, granted)
`
`David Caine, Reg. No. 52,683
`
`Matthew M. Wilk, (pro hac vice to befiled)
`
`Jeremy Cobb, (pro hacvice to befiled)
`
`All attorneys at Morrison & Foerster LLP and Arnold & Porter Kaye Scholer
`LLP for whom a motion to appearpro hacviceis filed
`
`The individual signing below hasthe authority to execute this document on
`
`behalf of Regeneron Pharmaceuticals, Inc.:
`
`By:
`
`Faaado @.a
`
`Name:
`
`Frank R. Cottingham, Ph.D., J.D
`
`Title:
`
`Date:
`
`VP, Associate General Counsel, Intellectual Property
`
`
`
`MaRcH 14, 2024
`
`1
`
`